OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Deciphering the Impact of HER2 Alterations on Non-Small-Cell Lung Cancer: From Biological Mechanisms to Therapeutic Approaches
Christophe Bontoux, Jonathan Benzaquen, Véronique Hofman, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 10, pp. 1651-1651
Open Access | Times Cited: 8
Christophe Bontoux, Jonathan Benzaquen, Véronique Hofman, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 10, pp. 1651-1651
Open Access | Times Cited: 8
Showing 8 citing articles:
HER2-targeted therapies beyond breast cancer — an update
Jeesun Yoon, Do‐Youn Oh
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 9, pp. 675-700
Closed Access | Times Cited: 15
Jeesun Yoon, Do‐Youn Oh
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 9, pp. 675-700
Closed Access | Times Cited: 15
Molecular principles underlying aggressive cancers
Ruth Nussinov, Bengi Ruken Yavuz, Hyunbum Jang
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 3
Ruth Nussinov, Bengi Ruken Yavuz, Hyunbum Jang
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 3
Current challenges and practical aspects of molecular pathology for non-small cell lung cancers
Paul Hofman, Sabina Berezowska, Daniel Kazdal, et al.
Virchows Archiv (2023) Vol. 484, Iss. 2, pp. 233-246
Open Access | Times Cited: 18
Paul Hofman, Sabina Berezowska, Daniel Kazdal, et al.
Virchows Archiv (2023) Vol. 484, Iss. 2, pp. 233-246
Open Access | Times Cited: 18
Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non–Small Cell Lung Cancer: Implications for Precision Medicine
Yurimi Lee, Boram Lee, Yoon‐La Choi, et al.
Modern Pathology (2024) Vol. 37, Iss. 6, pp. 100490-100490
Closed Access | Times Cited: 5
Yurimi Lee, Boram Lee, Yoon‐La Choi, et al.
Modern Pathology (2024) Vol. 37, Iss. 6, pp. 100490-100490
Closed Access | Times Cited: 5
Precision nanomedicine to treat non-small cell lung cancer
Akanksha Dessai, Usha Y. Nayak, Yogendra Nayak
Life Sciences (2024) Vol. 346, pp. 122614-122614
Open Access | Times Cited: 3
Akanksha Dessai, Usha Y. Nayak, Yogendra Nayak
Life Sciences (2024) Vol. 346, pp. 122614-122614
Open Access | Times Cited: 3
Progress of PD-1/PD-L1 inhibitor combination therapy in immune treatment for HER2-positive tumors
Sining Zhao, Yiwu Qiu, Meiqin Yuan, et al.
European Journal of Clinical Pharmacology (2024) Vol. 80, Iss. 5, pp. 625-638
Closed Access | Times Cited: 2
Sining Zhao, Yiwu Qiu, Meiqin Yuan, et al.
European Journal of Clinical Pharmacology (2024) Vol. 80, Iss. 5, pp. 625-638
Closed Access | Times Cited: 2
Deciphering the Anticancer Arsenal of Piper longum: Network Pharmacology and Molecular Docking Unveil Phytochemical Targets Against Lung Cancer
Venkatramanan Varadharajan, Ashwath Kumar Balu, Atul Shiju, et al.
International Journal of Medical Sciences (2024) Vol. 21, Iss. 10, pp. 1915-1928
Open Access | Times Cited: 2
Venkatramanan Varadharajan, Ashwath Kumar Balu, Atul Shiju, et al.
International Journal of Medical Sciences (2024) Vol. 21, Iss. 10, pp. 1915-1928
Open Access | Times Cited: 2
Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers
Zheng Yang, Jiayu Zou, Chen Sun, et al.
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 6
Zheng Yang, Jiayu Zou, Chen Sun, et al.
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 6
